Gentle swirling over 10 to 15 minutes solves most slow-dissolving cases
The Regulatory Background In late 2023, the FDA placed 19 widely used peptides on its Category 2 restricted list, effectively barring compounding pharmacies from preparing them
Common Side Effects When side effects occurred, they were typically mild, transient, and similar in frequency to placebo groups: Reported Adverse Effects Most Common (occurring in small percentage of participants): Mild to moderate headaches (most frequently reported, often resolving with continued use) Injection site reactions (minor redness, swelling, or irritation at injection site) Gastrointestinal effects (particularly at higher oral doses: mild nausea, diarrhea, flatulence) Fatigue (reported occasionally during initial adaptation period) Rare Events: One case of chest tightness was deemed possibly related to treatment in safety trials
The preservative issue is not mentioned
Some elevations may be due to laboratory assay interference or macro-B12 (B12 bound to immunoglobulins), which has no clinical significance
